 |
 |
1. Rotigotine transdermal system in a multicenter trial of patients with advanced-stage Parkinson's disease as adjunctive therapy to levodopa P LeWitt, P Nausieda, FL Chang, E Fazzini, D Truong, M Carpenter, K Sommerville, B Boroojerdi, SP650 Study Group S32.003, A184-185 Transdermal rotigotine can reduce off time without increasing troublesome dyskinesias, according to this study. Three hundred fifty-one PD patients with at least 2.5 hours daily off time were randomized to rotigotine 40 sq. cm, rotigotine 60 sq. cm, or placebo, for 29 weeks. Three quarters of patients completed the trial. Mean daily off time reduction was 2.7 hours. 2.1 hours, and 0.9 hours, respectively. There was no increase in on time with troublesome dyskinesias. Redness and itching at the application site, and edema, were greater in patients receiving rotigotine. Discontinuations due to adverse events occurred in 16% of patients receiving rotigotine, versus 8% of patients receiving placebo. Supported by Schwarz Pharma 2. Continuous dopaminergic stimulation with lisuride TTS (patch) in moderately advanced Parkinsonian patients T Dimitrova, W Bara-Jiminez, M Thomas, F Bibbiani, X Zhiang, T Chase S23.004, A185 Treatment with transdermal lisuride reduces motor fluctuations, according to this study. Twenty patients were randomized to transdermal lisuride or placebo for 16 weeks. UPDRS motor scores improved by 5 pts in patients receiving lisuride, versus 0 in those receiving placebo. Levodopa dose was reduced by 50% in patients receiving lisuride without loss of motor benefit. Dyskinesia scores did not change as a result of treatment. Night-time sleep, daytime somnolence, and quality of life all improved. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn